Logo
x

Search

Subscribe Now

Sarepta Therapeutics

Sarepta Therapeutics’ Elevidys Gains the US FDA’s Label Expansion Approval for Duchenne Muscular Dystrophy

Sarepta Therapeutics’ Elevidys Gains the US FDA’s Label Expansion Approval for Duchenne Muscular Dystrophy

  • June 21, 2024
PharmaShots Weekly Snapshots (June 19 – 23, 2023)

PharmaShots Weekly Snapshots (June 19 – 23, 2023)

  • June 24, 2023
Sarepta Therapeutics’ Elevidys Receives the US FDA’s Accelerated Approval for the Treatment of Duchenne Muscular Dystrophy

Sarepta Therapeutics’ Elevidys Receives the US FDA’s Accelerated Approval for the Treatment of Duchenne Muscular Dystrophy

  • June 23, 2023
PharmaShots Weekly Snapshots (Mar 15 - 19, 2021)

PharmaShots Weekly Snapshots (Mar 15 - 19, 2021)

  • March 19, 2021
Insights+: The US FDA New Drug Approvals in February 2021

Insights+: The US FDA New Drug Approvals in February 2021

  • March 18, 2021
Sarepta Therapeutics Collaborates with University of Florida to Accelerate the Development of Therapies for Rare Genetic Diseases

Sarepta Therapeutics Collaborates with University of Florida to Accelerate the Development of Therapies for Rare Genetic Diseases

  • August 12, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.